VANCOUVER, BRITISH COLUMBIA--(MARKET WIRE)--Sep 30, 2008 -- Perceptronix Medical Inc., a privately owned independent cytology laboratory specializing in early cancer detection tests, will present at the BioContact biopharmaceutical partnership symposium at Chateau Frontenac in Quebec City. The symposium will be held on October 2nd, 2008, at 2pm, Salle Petit Frontenac. Dr. Bojana Turic, President and CEO of Perceptronix will provide the Company overview and its' newest development and business strategies.

About Perceptronix Medical Inc.

Perceptronix Medical Inc. ("Perceptronix" or the "Company") is a privately owned independent cytology laboratory specializing in early cancer detection tests based on quantitative cytology. The Company's intention is to serve physicians in, Private surgical centers, outpatients in Diagnostic centers, Private Health Clinics, and Health Occupation Groups, Executive Health Services, International Screening Programs and various health organizations that focus on early cancer detection and are on demand for accuracy and efficiency. The company was founded from technology developed at the British Columbia Cancer Agency (BCCA) in Vancouver and has undertaken a dramatic shift in recent years from that of a product based technology sales company to a lab service oriented Company. The Company's mission is to provide a full complement of early cancer laboratory screening tests to the medical community.

About BioContact Quebec

BioContact Quebec is an annual biopharmaceutical conference which puts together companies, venture capital and technology transfer experts together.

     Contacts:
     Perceptronix Medical Inc.
     Darren Zilinsky
     Director of Finance
     (604) 629-8785
     Email: dzilinsky@perceptronix.com